Regnology, a pioneering technology firm dedicated to enhancing safety and stability in the financial markets, has successfully raised a remarkable $690 million in its latest funding round. Founded in 2021 through the collaboration of BearingPoint RegTech and Vizor Software, Regnology specializes in regulatory reporting solutions, serving over 34,000 financial institutions, 60 regulators, international organizations, and tax authorities worldwide. This significant capital injection comes at a crucial time as the firm seeks to further innovate its offerings and expand its global reach. With an impressive workforce of over 850 employees across 17 countries, Regnology is strategically positioned to leverage its unified data ingestion model, which allows clients to adapt quickly to evolving regulatory landscapes. The funding will be instrumental in accelerating research and development initiatives, enhancing product functionality, and driving operational efficiencies that ultimately translate into greater data quality and cost savings for its clients. Regnology’s commitment to providing robust regulatory solutions not only aids in compliance but also empowers market participants to thrive even amidst turbulent financial conditions. As the financial industry faces increasing regulatory pressures and demands for transparency, Regnology is poised to be a backbone in delivering the technology-driven solutions necessary for sustainable growth and stability in the sector. This funding marks a pivotal milestone for Regnology, underscoring investor confidence in its vision for a more secure and efficient financial ecosystem.
Regnology Secures $690 Million in Funding to Enhance Regulatory Reporting Solutions
Get the full Regnology company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Beeline Medicines
Beeline Medicines is a clinical-stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people living with autoimmune and inflammatory diseases. We are here to chart a new path for patients, rigorously pushing the science forward to deliver therapies that go straight to the drivers of immune dysfunction to define new treatment paradigms. Our portfolio is comprised of therapeutic candidates rooted in validated biology, powered by best-in-class molecular properties, and driven by an efficient clinical development strategy designed for differentiated, lasting impact for patients. Grounded in scientific rigor and driven by purpose, we get to what matters so that people living with immune-mediated diseases can live life fully.
$126.3M Series a
today
Revoraai
Most real estate businesses don’t have a lead problem. They have a conversion problem. Leads come in… But slow replies, missed follow-ups, and unqualified inquiries kill deals. That’s where I help. I build AI-powered systems that: • Instantly respond to new leads • Filter serious buyers • Follow up automatically • Turn conversations into site visits No manual chasing. No missed opportunities. Just a smarter way to convert leads into revenue. If you're in real estate and want to automate your lead flow, let’s connect.
$2.0M Seed
today
LEKO
LEKO Labs is accelerating the global transition to carbon negative construction with building materials powered by AI optimization and robotic manufacturing.
$9.0M Seed
today
Wolf-e Robotics
EU Manufacturer of Smart #UVC Disinfection Devices. Air Purifiers, Applied UV Robotics, Research & Development Platform. Gausium cleaning robots distributor. Democratizing clean air and surfaces in any indoor space. For collabs & enquiries, check our website: www.wolfe.ro.
$54.0K Unknown
today
OxidOS Automotive
OxidOS Automotive is building the next generation of software development tools and Operating Systems for Automotive ECUs, fully written in Rust. The OxidOS platform and Operating System allow automotive manufacturers and integrators to deploy safe and secure software faster, through development, debugging, and certification time reduction.
$54.0K Unknown
today